14 completed, 13 active not recruiting, 5 terminated, 4 recruiting. 32 Phase 1, 23 Phase 2, 1 Phase 3.
Follow Recurrent Follicular Lymphoma: new trials by email Literature Review of Recurrent Follicular Lymphoma trials Research Report on Recurrent Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 22 | 2025-11-17 | 2026-06-04 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Tazemetostat, Ublituximab, Umbralisib - Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2023-05-01 | 2023-05-31 | |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma Bendamustine Hydrochloride, Brentuximab Vedotin - Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Recruiting | University of California, Davis | 23 | 2020-12-04 | 2026-06-29 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Copanlisib, Gemcitabine, Carboplatin - Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | University of Washington | 12 | 2020-03-31 | 2023-06-29 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Laboratory Biomarker Analysis, Pembrolizumab, Rituximab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 2 | Terminated | University of Washington | 18 | 2018-03-23 | 2025-07-22 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2018-01-23 | 2026-07-08 |
Showing 20 of 43. Sign in to see all of them.
Lymphoma, Follicular (43) · Lymphoma, Mantle-Cell (26) · Lymphoma, B-Cell, Marginal Zone (22) · Lymphoma, Large B-Cell, Diffuse (22) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, B-Cell (14) · Lymphoma, Non-Hodgkin (11) · Lymphoma, T-Cell (8) · Burkitt Lymphoma (7) · Waldenstrom Macroglobulinemia (7) · Hodgkin Disease (6) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Hairy Cell (2)
Hemic and Lymphatic Diseases (43) · Immune System Diseases (43) · Immunoproliferative Disorders (43) · Lymphatic Diseases (43) · Lymphoproliferative Disorders (43) · Neoplasms (43) · Neoplasms by Histologic Type (43) · Lymphoma (42) · Lymphoma, Non-Hodgkin (32) · Lymphoma, B-Cell (21) · Hematologic Diseases (20) · Disease Attributes (15) · Leukemia (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15)
Lenalidomide (11) · Cyclophosphamide (8) · Biopsy (7) · Magnetic Resonance Spectroscopy (7) · CT-P10 (6) · Rituximab (6) · Specimen Handling (6) · fludarabine phosphate (6) · ibrutinib (5) · obinutuzumab (5) · pembrolizumab (5) · Bendamustine Hydrochloride (4) · Etoposide (4) · Carmustine (3) · Cytarabine (3)
National Cancer Institute (NCI) (6) · City of Hope Medical Center (5) · University of Washington (5) · Fred Hutchinson Cancer Center (3) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · Xinqiao Hospital of Chongqing (2) · AIDS Malignancy Consortium (1) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Beth Christian (1) · David Bond, MD (1) · Di Deng (1) · Jonsson Comprehensive Cancer Center (1) · Joseph Tuscano (1)
United States (37) · China (3) · Canada (1)
Alex F Herrera (2) · Joseph M Tuscano (2) · Stephen D. Smith (2) · Alexey Danilov (1) · Beth A Christian (1) · Beth Christian, MD (1) · Bhagirathbhai Dholaria, M.D. (1) · Bo Zhu, M.D., Ph.D. (1) · David Bond, MD (1) · Dipenkumar Modi, M.D. (1) · Francisco J Hernandez-ILizaliturri (1) · Hun Lee (1) · Jennifer E Amengual (1) · Jithma P. Abeykoon, MD (1) · John P. Leonard, MD (1)
PMID 34515338, PMID 28314699, PMID 33785483, PMID 34320785, PMID 34492703, PMID 34780125, PMID 36631449, PMID 37339586, PMID 37470137, PMID 37939259, PMID 39161543
P30CA016058 (2), P30CA016672 (2), P30CA033572 (2), P30CA093373 (2), K24CA201524 (1), N01CM00071 (1), N01CM62201 (1), P30CA014599 (1), P30CA015704 (1), P30CA022453 (1), P30CA069533 (1), P50CA097274 (1), R01CA219960 (1), R35CA197353 (1), U01CA062461 (1)